To promote the innovation of the source of new cancer drug creation, the first domestic medical enterprises linked top-level resource platform debuted

"The transformation of Chinese pharmaceutical development technology, 46% from enterprises, less than 10% from clinical.
transformation of Chinese pharmaceutical enterprises is the most important link and the real driving force of Chinese medicine innovation.
, president of the China Drug Promotion Association, said at the recent China Pharmaceutical Innovation Promotion Association's Clinical Research Summit on Anti-Tumor Innovative Drugs.
China Drug Promotion Association President Song Ruixuan for the Chinese Pharmaceutical Association anti-tumor drug clinical research professional committee of the first chairman Professor Li Jin issued a certificate of employment bridge: medical enterprises to promote scientific and technological innovation and international cooperation to further promote China's anti-tumor new drug research and development and tumor clinical practice, to solve the industry drug research and development enterprises clinical decoupling status quo, optimize China's anti-tumor new drug clinical research resources, The Chinese Drug Promotion Association set up anti-tumor clinical research professional committee.
the first professional committee on clinical research of anti-tumor drugs is composed of 77 experts from the field of clinical medicine, enterprise research and development, all of which are authoritative leading representatives in the field of cancer drug research and development in China.
Professor Li Jin of Oriental Hospital affiliated with Tongji University was elected as the first chairman of the admin committee, Professor Ma Jun of Harbin Institute of Hematology oncology, Professor Zhu Jun of Peking University Cancer Hospital, Dr. Yu Dechao of Xinda Biopharmaceuticals, and Dr. Hui Aimin of Shanghai Fosun Pharma were elected as vice-chairman.
16 relevant subject experts from all over the country were elected to the Standing Committee.
At the same time, Sun Yan, Academician of the Oncology Hospital of the Chinese Academy of Medical Sciences, Professor Guan Zhongzhen of Sun Yat-sen University Cancer Prevention and Control Center, Professor Yu Jinming of Shandong Cancer Hospital, Professor Qin Shuxuan of the Eastern War Zone General Hospital, Professor Wu Yilong of Guangdong Provincial People's Hospital, and Chairman Sun Fengyang of Jiangsu Hengrui Pharmaceutical Co., Ltd. jointly served as consultants to the admin committee.
, president of the Pharmaceutical Research Institute, said that innovation in the field of pharmaceutical research can not be sustained without international integration and sharing.
to put real innovators and clinical experts on a platform to discuss the development of industrial development and scientific and technological innovation, is the original intention of the establishment of the ad committee.
China Pharmaceutical Promotion Council will play the role of a platform and bridge to promote international cooperation, for China's new drug creation to provide a better platform and space.
The State Drug Administration (NMPA) Drug Review Center (CDE) Minister Yang Zhimin gave a speech to set the direction: new drug research and development to strengthen basic research around patient-centered China's new anti-tumor drug research and development started relatively late, but the pace of expansion is relatively fast, the new drug clinical research market resource allocation is uneven, low level of innovation, homogenization competition has seriously caused the crowding and overlap of new drug research and development resources to a certain extent.
Zhimin, Minister of the Drug Review Center (CDE) of the State Drug Administration (NMPA), was invited to attend the conference and analyzed the current situation of anti-tumor drug research and development in China and the considerations of drug review.
She believes that the future of new drug research and development should strengthen basic research, and constantly improve the systematic thinking ability of new drug research and development, drug-centered to patient-centered research and development thinking, drug review is also based on patient needs as the center. Yang Zhimin pointed out that the current global anti-tumor drug research and development is active, but clinical resources have not been converted into new drugs is a big problem,
"these problems include insufficient innovation, basic research needs to be strengthened;
" Combined with China's new drug creation situation, Chairman Li Jin also analyzed the current major problems, including foreign research mainly focused on the Western countries of high-risk tumor drug research and development, China's high-risk tumor species such as liver cancer, stomach cancer, esophageal cancer and other low attention;
Li Jin believes that to solve the problem of anti-tumor drug research and development in China, we should start with policy guidance, overall planning of clinical research and development, explore new modes of cooperation, quality control of clinical trials, research and development level of pharmaceutical companies and improve the level of major researchers, and so on, to provide more solutions.
Mouring for the Future: Promoting Innovation at the Source of New Drug Creation in China Based on this, Professor Li Jin said that in the next two years, the development priorities and plans of the newly established PHAR Clinical Research Committee on Oncology, one of which is to summarize and analyze the market data of China's new anti-tumor drug clinical research in response to the lack of innovation and the pile-up of research and development resources.
In the future, we will issue a semi-annual market analysis and early warning report on the research and development of new drugs for cancer, minimize the risk of homogenization competition, optimize the resources for research and development of new drugs, and speed up the process and listing of clinical research on new drugs with different target mechanisms in China.
The second is to strengthen the cooperation between anti-tumor new drug research and development enterprises and clinical research units, from the objective needs of clinical reality, patient characteristics and actual situation, strengthen communication with drug research and development enterprises, and formulate strategies and directions suitable for the research and development of new anti-tumor drugs in China;
also strengthen the training of clinical research practitioners of new drugs to improve the quality of clinical research of new drugs in China.
, it can enhance the overall strength of clinical research on new anti-tumor drugs in China and speed up the research and listing of new drugs.